Dr. Agarwal's Health Care Limited buys two Delhi-NCR centres
Key highlights
- Dr. Agarwal's agreed to pay Rs 55 crore for two Delhi-NCR centres that generated Rs 13.5 crore of last-12-month revenue.
- About Rs 33 crore of the acquisition consideration is payable upfront, with the balance linked to milestones over four years.
- Dr. Agarwal's raised its FY27 target to 65 facilities, including 55 surgical centres, after adding 39 facilities in H1.
- North-region H1 FY27 revenue rose 60% year on year to Rs 115 crore, and the network reached 36 facilities.
powered by IRIS

Dr. Agarwal's Health Care Limited has agreed to acquire two Delhi-NCR centres for Rs 55 crore after the practices generated about Rs 13.5 crore of revenue and Rs 7.16 crore of business earnings before interest, tax, depreciation and amortisation (EBITDA) in the preceding 12 months. Dr. Agarwal's will pay about Rs 33 crore upfront, with the balance linked to milestones over four years.
Know Dr Agarwals Health Care inside out
Results, valuation, peers and who's buying, in one view.
What did Dr. Agarwal's acquire in Delhi-NCR?
Dr. Agarwal's acquired two centres run by Dr. Anchal Gupta, one in Greater Kailash in South Delhi and another in Loni, Ghaziabad. Management said it acquired the entire business through a Business Transfer Agreement, or BTA. It described Dr. Gupta as an established practitioner whose local presence supports the company's South Delhi expansion strategy.
The transaction adds two tertiary centres to Dr. Agarwal's Delhi network, which had reached 15 facilities in 15 months after operations began in Q1 FY26. During Q2 FY27, the company opened 19 Greenfield facilities and added the two acquired centres, rather than opening 21 Greenfield sites. Management said the Greater Kailash practice strengthens its position in South Delhi, while the Loni site extends the network in Ghaziabad.
Dr. Agarwal's has structured the consideration rather than paying the full Rs 55 crore on completion. Chief Financial Officer Yashwanth Venkat said about Rs 33 crore will be paid upfront and the remaining amount will be paid over four years against specified milestones. Management did not disclose the individual milestones, their operating measures or the timing of each deferred instalment.
Why did Dr. Agarwal's buy centres instead of building them?
Dr. Agarwal's said the acquisition is a selective bolt-on transaction within a predominantly Greenfield expansion model, rather than a change in its organic-growth strategy. Management said some Delhi micro-markets are led by doctors with strong local practices, and that this two-centre transaction fits its expansion plan in South Delhi. It also said the company had not made an acquisition for some time before this deal.
Greenfield development remains Dr. Agarwal's principal growth engine, with 185 such facilities added since FY23. The company added 39 facilities in H1 FY27, including 34 surgical centres, and raised its FY27 target to 65 facilities from 60. Its revised plan calls for 55 surgical centres, up from the earlier target of 40, and 10 primary centres.
Management said future acquisitions must meet two conditions: an acceptable valuation multiple and a strategic fit with the company's expansion plan. It specifically said it is not seeking acquisitions in Chennai, Bengaluru or Hyderabad, where it already has substantial operations. In newer markets such as Delhi-NCR, management said a bolt-on may be considered when it brings a reputable practice and supports a defined micro-market strategy.
The Greenfield rationale is centred on surgical facilities, which management said average Rs 75 lakh to Rs 80 lakh in monthly revenue. Management also cited faster break-even at several recent centres in core markets as support for further openings in existing locations and newer markets, including Delhi-NCR and Mumbai. Acquisitions, by contrast, remain contingent on the availability and strategic suitability of partners.
Got a follow-up? Ask IRIS
How is Dr. Agarwal's expanding across regions?
Dr. Agarwal's North region reported the fastest revenue growth in H1 FY27, rising 60% year on year to Rs 115 crore, while its network reached 36 facilities. The company commissioned five Greenfield centres in Delhi-NCR during the quarter across Noida, Ghaziabad and Delhi, before the two acquired sites are counted. Management said it expects to add another eight to 12 Delhi-NCR centres over the next nine to 12 months.
The wider programme has led management to revise FY27 capital-expenditure guidance to Rs 500 crore from Rs 400 crore indicated on the Q1 call. The increase accompanies the target of 65 facilities and 55 surgical centres. After 39 additions in H1 FY27, Dr. Agarwal's plans another 26 facilities in H2 FY27, including 21 surgical facilities.
North's 60% growth exceeded South's 24.6%, West's 30% and East's 30%, although North remained smaller in revenue than each of South and West. In the West, Dr. Agarwal's operated 55 facilities after eight new surgical Greenfield additions in H1 FY27. Management said it had signed agreements for more Mumbai micro-markets and expects additional rollouts there within the next six months.
What does the deal mean for Dr. Agarwal's financial plan?
Dr. Agarwal's reported revenue from operations of Rs 1,269 crore in H1 FY27, up 28.7% from Rs 986 crore in H1 FY26, while EBITDA under Indian Accounting Standards, or Ind AS, increased 27% to Rs 362 crore. Against that group revenue base, the acquired practices' Rs 13.5 crore of last-12-month revenue are relatively small. Management nevertheless positioned the transaction as a targeted way to build coverage in Delhi-NCR.
Same-store sales growth, or SSSG, was 17.7% in H1 FY27 and 18.8% in Q2 FY27. Management attributed the H1 figure to about 8% volume growth, comprising 7.5% outpatient-department growth and 0.5% conversion growth, plus 9.5% value growth. It said premiumisation accounted for about 8% of value growth and price for the remaining 1.5%.
The company is also funding the ramp-up of recent openings. Management cited about Rs 42 crore of losses over the past six months for the FY26 and FY27 facility cohorts, while separately putting FY27-cohort losses at Rs 18.2 crore and FY26-cohort losses at Rs 20.12 crore. The disclosed cohort figures do not reconcile to the stated Rs 42 crore total, and management did not provide a reconciliation during the call.
Surgical services accounted for 66% of H1 FY27 group revenue, compared with 22% from optical products and pharmacy and 12% from diagnosis, consultations and other non-surgical treatment. Dr. Agarwal's performed about 1.87 lakh surgeries in the half year, up 19% year on year. Management said the higher target for surgical sites reflects their throughput, while the acquired tertiary centres provide an established operating base in Delhi-NCR.
Conclusion
The Rs 55 crore transaction gives Dr. Agarwal's two established Delhi-NCR practices with Rs 13.5 crore of last-12-month revenue and Rs 7.16 crore of business EBITDA, while only Rs 33 crore is due upfront. It supplements an expansion programme that added 39 facilities in H1 FY27, rather than replacing the company's Greenfield-led model. The purchase also adds capacity in the North, where revenue rose 60% year on year to Rs 115 crore.
The next disclosed markers are delivery of the balance consideration over four years against milestones, integration of the Greater Kailash and Loni sites, and execution against the revised FY27 target of 65 facilities. Management plans 26 further openings in H2 FY27, including 21 surgical centres, under its revised Rs 500 crore capital-expenditure plan. It has also said it will assess further bolt-on acquisitions only when valuation and strategic-fit conditions are met.


